Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106075 | 1.00 | MAPT (0.67) | MAPTL3MBTL1KMT2AMEN1ATM | |
| SCHEMBL914510 | 1.00 | MAPT (0.67) | MAPTL3MBTL1KMT2AMEN1ATM | |
| Hydrochloric Acid SCHEMBL1604706 | 0.98 | MAPT (0.65) | MAPTL3MBTL1KMT2AMEN1ATM | |
| Hydrochloric Acid SCHEMBL1604707 | 0.98 | MAPT (0.65) | MAPTL3MBTL1KMT2AMEN1ATM | |
| SCHEMBL16838967 | 0.90 | MAPT (0.56) | MAPTL3MBTL1KMT2AMEN1ATM | |
| SCHEMBL6376551 | 0.89 | MAPT (0.67) | MAPTL3MBTL1KMT2AMEN1ATM | |
| SCHEMBL1878484 | 0.86 | SMN1; SMN2 (0.53) | MAPTL3MBTL1KMT2AMEN1SIGMAR1 | |
| SCHEMBL1878485 | 0.86 | SMN1; SMN2 (0.53) | MAPTL3MBTL1KMT2AMEN1SIGMAR1 | |
| SCHEMBL30929593 | 0.86 | SMN1; SMN2 (0.53) | MAPTL3MBTL1KMT2AMEN1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27396543 | 0.85 | SMN1; SMN2 (0.51) | MAPTL3MBTL1KMT2AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0105092-A2 | A thrombolytic agent | Amano Seiyaku Kabushiki Kaisha (JP) | 1984-04-11 | — | — | EP | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| EP-4457224-A1 | HETEROCYCLIC COMPOUNDS | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-118451073-A | Heterocyclic compounds | 百济神州有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-0393424-B1 | Process for the preparation of 2,7-Diazabicyclo(3.3.O)octanes | BAYER AG (DE) | 1995-09-27 | — | — | EP | disclosed |
| US-5344942-A | Enantiomorphs and induction | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1994-09-06 | — | — | US | disclosed |
| US-5284855-A | Broad-spectrum antibiotics; gramnegative and -positive bacteria, esp. Enterobacter | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| EP-0565969-A1 | Tricyclic lactols, their use as resolving agents and processes for their production | DSM Chemie Linz GmbH (AT) | 1993-10-20 | — | — | EP | disclosed |
| US-5241076-A | 1,4-diazatricyclo [6.3.0.0]undecanes | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| US-5202337-A | Antibacterial agent, feed additive | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |
| US-5177210-A | Preparation of 2,7-diazabicyclo(3.3.0)octanes | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-05 | — | — | US | disclosed |
| EP-0481274-A1 | 7-(2,7-Diazabicyclo[3.3.0]octyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1992-04-22 | — | — | EP | disclosed |
| US-5071999-A | Preparation of 2,7-diazabicyclo[3.3.0]octanes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0393424-A2 | Process for the preparation of 2,7-Diazabicyclo(3.3.O)octanes | BAYER AG (DE) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | MAPT 3357/4885L3MBTL1 3828/4885KMT2A 3652/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | MAPT 4503/4885L3MBTL1 3558/4885KMT2A 2162/4885 |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | NFATC1, CD4, ACIN1 | MAPT 3912/4885L3MBTL1 4624/4885KMT2A 2438/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | MAPT 3912/4885L3MBTL1 4624/4885KMT2A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.